Maria Artunduaga Presents Samay at LSI USA ‘23

Transcription

Maria Artunduaga  0:06  

Good afternoon, everyone. I'm Dr. Maria Artunduaga scientist and CEO of Samay. An AI enabled monitoring platform for respiratory health anywhere. The company was born from personal tragedy after I lost my grandmother to misdiagnosed COPD exacerbation and in days I made it my life's mission to transform respiratory care with novel digital biomarkers. When she passed, one of the things that I realized was that respiratory diseases not only affect millions of people, they are very expensive to treat. A COPD exacerbation event cost $28,000, which is driving an estimate of $800 billion in the next 20 years. And it doesn't stop there. Because asthmatics are also very expensive, long COVID Patients are projected to become the prices patients for health care systems to. Not surprisingly, because of a pandemic $3 billion dollars have been spent the remote monitoring tools in the last three years. Just last year alone in medical technol technology. The three highest unicorn valuations were remote monitoring platforms. The RPM market is expected to reach $175 billion dollars globally. That's about the US oncology market today. And it's great that we are investing in remote monitoring and tools finally to enable telemedicine but respiratory is still plagued with weak data quality as pyrometry, for example, it's very hard to do, and patients just don't like doing it. pulse oximetry, for example, it doesn't work when you're moving, or when you have color skin like me. And then questioners the standard of care. They miss 50% of the exacerbations. So I get this question a lot. Maria, yep. Why is this happening? It turns out that the lungs are very hard to assess. They are these are organs that are full of air and technology that we have today. For Home outside of a hospital, they don't work altra sound. This is a direct consequence of the fact that we are investing most of our of our public and private pawns into our various verticals like surgery, neurology, cardiovascular that has not a single breakthrough in pulmonary medicine, or a plus not a diagnostic in the last 50 years. So what's the innovation. So some eyes based in various strong science, it has been already demonstrated that low frequency sound, not ultra sound. audible sound can figure out volumes of air, especially in the lung. So we have this wearable device, it's called CLB is a prototype still, we place it on the chest, we inject signals on one end, we transmitted through the chest. And then on the other end, we are listening. We transmit that data to an app and later on to the cloud, where additional algorithms are figuring out pulmonary function in real time. In the next few years, we're expecting to accurately diagnose exacerbations and even predict them. And the innovation doesn't stop there. It doesn't stop there because we really want to streamline care coordination while fully engaging patients at risk of exacerbations. We just don't want to, we don't want to be another remote monitoring play. We truly want to close the loop from disease identification all the way to full escalation of exacerbation events. We need to do this because people are dying from exacerbations, just like my grandmother. It takes about five days to get the care that you need if you are exacerbating instead with Tildy. When you put on your chest for about three weeks, we can figure out your lung function. We can know when it's a gliding, we can start doing therapeutics early on. It could be non invasive ventilation, COVID medicine, it could be even pulmonary rehab, we can prevent hospitalizations, and obviously a lot of the cost. So far, we analyzed only 15% of the data per patient and we are almost about to reach FDA standards, several parameters on pulmonary endpoints against PFDs plethysmography CT scan and even a standardized questionnaires. What I'm more excited about is the fact that we can actually detect air trapping. air trapping is an early biomarker of exacerbation detection. air trapping also can show years before Aspiro metric can even detect or diagnose COPD, so our impact eventually could be great. Our initial target that target market is COPD, there are 30 million Americans affected by it in a bottom up approach. We can reach them through different Rent verticals aways. There is research readmission, remote monitoring programs and even patients, people sorry smokers 18 million people who have not been diagnosed with COPD, we will actually diagnose them. Ideally, we could actually get to a market of about four to 14.5 or $15 billion in the US. Our business model, we are a service based model we sell to multiple clients. For a strategic decentralized trials, we are pricing against our competitors. For pulmonary practices. Again, we don't want to reinvent the wheel remote monitoring models where we haven't on our back end the billing process, we keep 50% of the payment. And then for value based care networks, we have already talked in conversations with a lot of them, we charge them a yearly service subscription for $3,000. That's about 1/3 of the savings that we can generate for them. We have also done a lot of customer discovery, and we decided to go this way in all for go to market strategy. We will start with a research project for a research product next year working with our strategics we already secure a letter of intent. That's 510 k sorry, that's a class one registered device, followed by Val value based care models and pulmonary practices with a 510 K. It's just easier to work with them their cell cycles are way shorter, and ideally later on with hospital networks and with payers. Of course, a lot of other companies have recognized the problem too. We still believe that we are the most relevant because we can actually tell you your lung function. This is not symptoms. We can do this without asking you to blow through anything. And more importantly, we can detect exacerbation biomarkers like no other. We are a team of 17 led by Ricardo Garcia. He's a hard word. So for an audio engineer, his scope runs in 3 billion devices every day worldwide. I'm a former clinician, I publish New England Journal medicine nature PNAS PNAS. I've been aware that in the past and I've raised money before, we have assembled a very strong commercial team. They have done it before anything from every experiences, reimbursement codes, approve merger art with acquisitions, they help sell companies, they have secure patents. In less than eight months after our first VC check, we were able to prove our concept. We secure our technology enhancement project with an a strategic and we were able to put together a team of 15 diverse individuals. We have a clear pathway for market and trends by 2025, again is starting with a classroom product for research purposes with strategics by 2024, followed by a 510 K we have already identified three predicates and ideally we will be cashflow positive with a predictive algorithm by 2728. The potential for this company with just one additional indication is about $15 billion. Just in the US, we need to remember that about 10% of the world's population is going to be affected by a chronic respiratory conditions the next decade, thanks to COVID air pollution and unfortunately, climate change. We have a track record of investor capital efficiency we've raised so far 3.7 million. Half of our money's coming from grants. We have six issued patents we have proved our concept. We have a letter of intent from our strategic for a potential recurring revenue of a million dollars if we secure that contract. In 90 days, we are preparing to raise around a 5 million to hit to commercialize EPS or to regulatory milestones on a commercial pilot with that a strategic if you're interested in joining helping me advising me on a force investing in some AI, please reach out this is my contact information. You can look me on the app Maria Artunduaga. very memorable name. That's it. Thank you very much.